On the same note, an additional variant was identified within CLCF1, which is involved in the signalling of crucial cytokines for both RA and PsA and targeted by already available therapies (i.e., tocilizumab and sarilumab) [10,11]. This evidence concerns the gene CLCF1 and rheumatoid arthritis.